CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

Condition:   BCCs in Gorlin Syndrome Patients Interventions:   Drug: PTX-022;   Drug: Vehicle comparator Sponsor:   Palvella Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials